Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.
| MER Indicator |
MER description |
Target Fiscal Year |
Target |
| PrEP_NEW |
25-29, Male |
2019 |
655 |
| PrEP_NEW |
30-34, Male |
2019 |
452 |
| PrEP_NEW |
35-39, Male |
2019 |
318 |
| PrEP_NEW |
40-49, Male |
2019 |
232 |
| PrEP_NEW |
Male 15-19 |
2019 |
25 |
| PrEP_NEW |
Male 20-24 |
2019 |
391 |
| PrEP_NEW |
Male 50+ |
2019 |
25 |
| PrEP_NEW |
MSM |
2019 |
2,100 |
| PrEP_NEW |
Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection |
2019 |
2,100 |
| TX_CURR |
25-29, Female, Positive |
2019 |
4,610 |
| TX_CURR |
25-29, Male, Positive |
2019 |
3,592 |
| TX_CURR |
30-34, Female, Positive |
2019 |
12,514 |
| TX_CURR |
30-34, Male, Positive |
2019 |
9,600 |
| TX_CURR |
35-39, Female, Positive |
2019 |
14,352 |
| TX_CURR |
35-39, Male, Positive |
2019 |
17,820 |
| TX_CURR |
40-49, Female, Positive |
2019 |
15,936 |
| TX_CURR |
40-49, Male, Positive |
2019 |
24,545 |
| TX_CURR |
Age/Sex: 15-19 Female |
2019 |
448 |
| TX_CURR |
Age/Sex: 15-19 Male |
2019 |
488 |
| TX_CURR |
Age/Sex: 20-24 Female |
2019 |
1,105 |
| TX_CURR |
Age/Sex: 20-24 Male |
2019 |
1,359 |
| TX_CURR |
Age/Sex: 50+ Female |
2019 |
7,484 |
| TX_CURR |
Age/Sex: 50+ Male |
2019 |
8,751 |
| TX_CURR |
Number of adults and children receiving antiretroviral therapy (ART) |
2019 |
122,671 |
| TX_CURR |
Sum of Age/Sex disaggregations |
2019 |
936 |
| TX_NEW |
25-29, Female, Positive |
2019 |
1,539 |
| TX_NEW |
25-29, Male, Positive |
2019 |
2,537 |
| TX_NEW |
30-34, Female, Positive |
2019 |
3,498 |
| TX_NEW |
30-34, Male, Positive |
2019 |
4,118 |
| TX_NEW |
35-39, Female, Positive |
2019 |
2,683 |
| TX_NEW |
35-39, Male, Positive |
2019 |
5,462 |
| TX_NEW |
40-49, Female, Positive |
2019 |
3,079 |
| TX_NEW |
40-49, Male, Positive |
2019 |
5,080 |
| TX_NEW |
By Age/Sex: 15-19 Female |
2019 |
95 |
| TX_NEW |
By Age/Sex: 15-19 Male |
2019 |
130 |
| TX_NEW |
By Age/Sex: 20-24 Female |
2019 |
327 |
| TX_NEW |
By Age/Sex: 20-24 Male |
2019 |
960 |
| TX_NEW |
By Age/Sex: 50+ Female |
2019 |
1,341 |
| TX_NEW |
By Age/Sex: 50+ Male |
2019 |
1,458 |
| TX_NEW |
By Key populations: People who inject drugs (PWID) |
2019 |
6,773 |
| TX_NEW |
Number of adults and children newly enrolled on antiretroviral therapy (ART) |
2019 |
32,397 |
| TX_NEW |
Sum of Age/Sex disaggregates |
2019 |
4,311 |
| TX_PVLS |
Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months |
2019 |
113,872 |
| TX_PVLS_den |
Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine |
2019 |
50,847 |
| TX_PVLS_den |
Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted |
2019 |
2,676 |
| TX_PVLS_den |
Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine |
2019 |
57,343 |
| TX_PVLS_den |
Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted |
2019 |
3,021 |
| TX_PVLS_den |
Denominator: Indication: Routine |
2019 |
108,188 |
| TX_PVLS_den |
Denominator: Indication: Targeted |
2019 |
5,698 |
| TX_RET |
Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) |
2019 |
17,330 |
| TX_RET |
Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) |
2019 |
19,532 |
| TX_RET |
Number of adults and children who are still alive and on treatment at 12 months after initiating ART |
2019 |
36,859 |
| TX_RET |
Numerator by Status: Pregnant |
2019 |
1,002 |
| TX_RET |
Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up |
2019 |
40,957 |
| TX_RET_den |
Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) |
2019 |
19,256 |
| TX_RET_den |
Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) |
2019 |
21,708 |
| TX_RET_den |
Denominator by Status: Pregnant |
2019 |
1,116 |
| TX_TB |
Number of ART patients who were screened for TB at least once during the reporting period |
2019 |
122,671 |
| TX_TB_den |
Denominator: By Aggregated Age/Sex: 15+, Female |
2019 |
57,661 |
| TX_TB_den |
Denominator: By Aggregated Age/Sex: 15+, Male |
2019 |
65,017 |
| TX_TB_den |
Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay |
2019 |
9,808 |
| TX_TB_den |
Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease |
2019 |
9,808 |
